Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Journal of Infectious Diseases|August 2, 2025
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 in Long-Term CareLindsay Zielinski, Kristin Andrejko, Nong Shang, et al.
Vaccine|August 13, 2021
ICD-10 anaphylaxis algorithm and the estimate of vaccine-attributable anaphylaxis incidence in MedicareRavi Goud, Deborah Thompson, Kerry Welsh, et al.
Pharmacoepidemiology and Drug Safety|June 7, 2019
Zostavax vaccine effectiveness among US elderly using real-world evidence: Addressing unmeasured confounders by using multiple imputation after linking beneficiary surveys with Medicare claimsHector S Izurieta, Xiyuan Wu, Yun Lu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 19, 2020
Comparative Effectiveness of Influenza Vaccines Among US Medicare Beneficiaries Ages 65 Years and Older During the 2019-2020 SeasonHector S Izurieta, Michael Lu, Jeffrey Kelman, et al.
Pharmacoepidemiology and Drug Safety|January 22, 2025
Lessons Learned From Characterizing Long COVID Among US Medicare BeneficiariesYun Lu, Arnstein Lindaas, Hector S Izurieta, et al.
American Journal of Public Health|October 23, 2024
Trends in Medical Encounters Involving Cannabis-Related Disorders Among US Medicare Beneficiaries, 2017-2022Silvia Perez-Vilar, Sara Kazemian, Christina Greene, et al.
The Journal of Infectious Diseases|July 11, 2019
Effect of Age on Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries Aged ≥65 YearsYun Lu, Yoganand Chillarige, Hector S Izurieta, et al.
The Journal of Infectious Diseases|October 15, 2024
Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older During the BA.1/BA.2 Omicron PeriodYun Lu, Kathryn Matuska, Rowan McEvoy, et al.
Vaccine|March 13, 2026
A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and olderRowan McEvoy, Jessica Rose Hervol, Yike Zhang, et al.
Open Forum Infectious Diseases|March 20, 2024
Real-world Effectiveness of mRNA COVID-19 Vaccines Among US Nursing Home Residents Aged ≥65 Years in the Pre-Delta and High Delta PeriodsYun Lu, Arnstein Lindaas, Kathryn Matuska, et al.
Pageof 2